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Abstract
Repaired tendons may be complicated by progressive fibrosis, causing adhesion formation or tendon softening leading to
tendon rupture and subsequent reduced range of motion. There are few therapies available which improve the gliding of
damaged tendons in the hand. We investigate the role of Mannose 6-phosphate (M6P) in a 600 mM hypertonic solution
(Adaprev) on tendon adhesion formation in vivo using a mouse model of severed tendon in conjunction with analysis of
collagen synthesis, cellular proliferation and receptors involved in TGF beta signalling. Cytotoxicity was assessed by
measuring tissue residency, mechanical strength and cell viability of tendons after treatment with Adaprev. To elicit
potential modes of action, in vitro and ex vivo studies were performed investigating phosphorylation of p38, cell migration
and proliferation. Adaprev treatment significantly (p,0.05) reduced the development of adhesions and improved collagen
organisation without reducing overall collagen synthesis following tendon injury in vivo. The bioavailability of Adaprev saw
a 40% reduction at the site of administration over 45 minutes and tendon fibroblasts tolerated up to 120 minutes of
exposure without significant loss of cell viability or tensile strength. These favourable effects were independent of CI-MPR
and TGF-b signalling and possibly highlight a novel mechanism of action related to cellular stress demonstrated by
phosphorylation of p38. The effect of treatment reduced tendon fibroblast migration and transiently halted tendon
fibroblast proliferation in vitro and ex vivo. Our studies demonstrate that the primary mode of action for Adaprev is
potentially via a physical, non-chemical, hyperosmotic effect.
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Introduction
Repaired tendons may be complicated by the paradoxical
problems of fibrosis, causing adhesion formation, and tendon
softening, causing tendon rupture and/or reduced range of
motion. Numerous therapies have been investigated with the
aim of improving the gliding function of damaged tendons in the
fingers [1]. In England between 2012 and 2013, 17555 primary
tendon repairs were performed together with 3537 tendon freeing
procedures (tenolysis) as a result of adhesions [2]. The average
length of treatment in splint is 6 weeks and estimated time to full
functional recovery around 12 weeks [3]. Around 28% [4] to 57%
[5] of patients have a fair to poor functional recovery after flexor
tendon surgery and failed repairs account for 3.9% [6] to 30% of
patients [7]. Although there has been a recent trend to advocate
cell based [8] and growth factor directed therapies [9] in tendon
injuries few strategies have been adopted clinically.
Wound healing and the process of scar formation is a
mammalian response to injury that applies to many tissues [10]
including flexor tendon healing. Adhesion formation between the
sheath and tendon arises from a combination of cellular
proliferation and collagen deposition within the surrounding
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injured tissue, restricting gliding function that peaks at around
three to four week and matures by eight weeks [11]. Transforming
growth factor beta 1 (TGF-b1) has been implicated in adhesion
formation [12], and manipulating TGF-b via neutralising
antibodies post-surgery reduces the number and size of adhesions
[13]. Mannose-6-Phosphate (M6P) has been demonstrated to
reduce active TGF-b1 expression on cultured tendon fibroblasts
and improved range of movement in a rabbit flexor tendon injury
model [14]. Studies of M6P in relation to skin scarring also
demonstrate improvement in scar cosmesis and accelerated return
of normal dermal architecture [15]. However the mechanism by
which M6P reduces adhesion formation is still unclear and it is
questionable whether its mode of action is via the inhibition of the
TGF-b1 pathway. Indeed, TGF-b1 and its receptors are only
expressed at significant levels 7 to 28 days after injury [12,16] but
the administration time frame of M6P in studies are inconsistently
earlier [14]. It has also been established that latent TGF-b is
activated by a range of CI-M6PR independent mechanisms [17]
and that mannose phosphorylation has little role in inhibiting the
activation of TGF-b1 [18], which indicates there may be other
mechanisms for M6P to elicit its antiscarring effect [19], and anti-
adhesion effect [14,20]. Thus, we set out in this study to elicit
whether M6P was effective at reducing tendon adhesions and if so
by which biological effects and by which potential mechanisms.
Materials and Methods
Preparation of Mannose 6-Phosphate and Glucose 6-
Phosphate
Mannose 6-Phosphate (M6P; Sigma-Aldrich, UK) was origi-
nally prepared for study using 14 mg/ml, 56 mg/ml and 169 mg/
ml to produce 50 mM, 200 mM, and 600 mM solutions
respectively.
Mannose 6-Phosphate (M6P; Sigma-Aldrich, UK), or Glucose
6-Phosphate (G6P; Sigma-Aldrich, UK) was weighed to make up a
600 mM (169.26 mg/mL) solution, which was then placed into a
volumetric flask and Phosphate buffered saline (PBS, Life
Technologies, USA.) added (approximately 2 mL less than the
total desired volume was prepared to allow for neutralisation). The
solution was inverted several times to aid dissolution. A 100 mL
pipette (Gilson, UK) was used to slowly add 10M Sodium
Hydroxide (NaOH; Sigma-Aldrich, UK) drop wise to the solution,
swirling after each addition, until the solution was neutralised. The
solution was allowed to stand at room temperature for 30 min to
allow any remaining M6P or G6P to dissolve. After 30 minutes,
the pH of the solution was determined and adjusted to pH 7.0
(60.5) using 10M NaOH. From this stock solution dilutions were
made to prepare 50 mM, 200 mM and 600 mM solutions using
PBS.
In subsequent studies osmolality was checked at 150 mM,
300 mM and 600 mM using a 3320 Micro-osmometer (Advanced
Instruments Inc, USA.) and preparations specifically of 50 mM,
200 mM and 600 mM (Adaprev) were used for study.
Solution distribution study
Ten mouse digits had 2 mL of 1:50 Vybrant DiI solution
(Molecular Probes, USA) administered into the flexor tendon
sheath under 20x magnification. Five mice were harvested
immediately after wound closure and five were harvested one
day after administration of DiI. Following fixation, decalcification,
wax processing and serial sectioning, images were captured using a
SPOT camera (Diagnostic instruments Inc, USA) mounted on a
Leica DMRB microscope (Leica Microsystems, Germany) using a
5x objective. Images were uploaded into a 3D reconstruction
program (Reconstruct) [21] and a 3D representation of solute
distribution was produced.
Therapeutic study
The effect of treatment was reviewed at three weeks following
injury, the point of greatest fibroblast activity and adhesion
deposition, and also reviewed at eight weeks coinciding with the
end of the synthetic phase [11].
Reconstituted M6P at doses 50 mM (low), 200 mM (moderate)
or 600 mM (high; Adaprev) were used for different treatment
groups. Recombinant human TGF-b1 (R&D systems, USA.) was
used at a concentration of 10 nM. This was reconstituted in sterile
4 mM Hydrochloric acid (HCl; Sigma-Aldrich, UK) and 0.1%
human serum albumin solution (Sigma-Aldrich, UK) and selected
for its pro-fibrotic effects as a positive control. This dose was
selected from dosage studies performed on skin wounds in rats
[22]. Normal 0.9% saline was used on the contralateral wounded
limb as a control. The allocation of treatment to each mouse digit
was performed in a single blinded randomised fashion to minimise
study bias and the study designed with n= 5 per treatment at each
time point.
Mice Operative model
All work was approved by the Local Ethical Review Committee
at the University of Manchester, and complied with British Home
Office regulations on care and use of laboratory animals (Project
licence Number PPL 40/2734). Our previously described adhe-
sion model [11] was used to assess the effects of Adaprev therapy.
The mouse in vivo study used the hindpaw deep digital flexor of
male C57/BL6 mice aged between 10 and 12 weeks (25–30 g)
(Charles River, UK). Surgery was performed under a standard
mouse general anesthetic protocol (Induction using 4% isoflurane
(Abbott, UK) and 4 l/min oxygen driver, maintenance 2%
isoflurane with 2 l/min oxygen driver and 1.5 l/min nitrous oxide
[BOC healthcare, UK).
Under tourniquet control a partial laceration wound was
performed that involved approximately 50% of hindpaw flexor
tendon fibres. Depending on the study allocation, wounds were
treated with either 0.9% saline, PBS, TGF-b1 10 nM or M6P
(n= 5 per treatment group) at 50 mM, 200 mM or Adaprev,
infiltrated into the sheath. A proximal tenotomy was performed to
avoid the tendon reuniting and minimise tendon glide at the site of
injury. The skin was closed with interrupted 10/0 polyamide
sutures (BBraun Medical, Germany). Mice were euthanized at
three weeks and eight weeks following injury. Four hours before
tissue collection, each mouse had 10 ml/g of 5-bromo-2-deoxyur-
idine (BrdU, GE Healthcare, UK) injected into their peritoneal
cavity.
Both hindpaws were harvested and immediately fixed, decalci-
fied, tissue processed, serially sectioned at 7 mm and stained with
Haematoxylin and Eosin Y (H&E) (Thermo Scientific Raymond
Lamb, UK.) and picosirius red (Abcam, UK.) as per manufacturer
guidance.
Five sample sections per tendon, 56 mm apart, representing the
adhesion and covering 280 mm depth were analysed using Image
Pro Plus version 4.5 (Media Cybernetics, USA). From these
calibrated images, adhesion length was digitally measured. The
area of adhesion and the volume of the deep digital flexor tendon
were calculated based on Cavalieri principles [23].
To investigate the remodelling of the tendon architecture,
standard histological images were layered onto polarised images
for quantification using a modified method from Lin et al [24]
(Figure S1). Images of H&E stained histology with bright field
microscopy were captured in the same position with the polarising
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filter (Leica Microsystems, Germany) sited at 45u to the tendon
which gave maximum polarisation through aligned collagen.
Images were analysed as before and the area of tendon mapped
using the outlining function on H&E stained images. The latter
image was layered onto the polarised image to generate a precise
outline on the polarised image. The quantification counter in
Image pro plus, all bright (polarising) areas were quantified as a
percentage of the overall tendon area. Six non wounded tendons
were also quantified to establish base line levels of polarisation in
unwounded tendon. Values measured were tendon volume (mm3),
adhesion area (mm2) and percentage polarisation (%).
Immunohistochemical Analysis
For analysis of synthetic and proliferative activity between
untreated and Adaprev treated tendons 3 representative slides
were taken from each serial sectioned digits and antibody stained
for 1:200 (v/v) dilution BrdU (Abcam, UK) and 1:200 (v/v)
dilution heat shock protein 47 (Hsp47; Stressgen, USA), in
triplicate per mouse digit. Immunoperoxidase techniques were
standardized as previously described [11]. Slides to be stained for
Hsp47 antibodies were pretreated with 10 minutes in 4 mol/L
HCl followed by 5 minutes in pH 8.2 borate buffer (Sigma-
Aldrich, UK.) prior to antibody staining, and a specific mouse on
Figure 1. Effect of M6P on tendon adhesion area and tendon structural organisation. A. Effect of M6P at increasing doses on adhesion
area at 3 weeks (most synthetic period) and 8 weeks (end of tendon healing). B. Effect of M6P at increasing doses on tendon organisation as
measured by quantitative polarisation. Effect of TGFb-1 at 2.5 ng was used as a positive control but did not significantly increase adhesion formation
or improve tendon organisation (p.0.05). All values of treated tendons were compared to contralateral saline controls. Unwounded controls were
also measured for polarisation normalisation. Significant reductions in adhesion formation were seen in 50 mM M6P treated group at three weeks
and in 600 mM M6P treated groups at eight weeks. Improvement in tendon organisation was significant with 600 mM M6P treatment. Significant
differences with p,0.05 on paired t-testing are indicated by an asterisk.
doi:10.1371/journal.pone.0112672.g001
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mouse kit (Vector Laboratories, UK) was used. For BrdU
antibodies, a standard rabbit anti-rat biotinylated secondary
antibody (Vector Laboratories, UK) was used and amplified using
the Elite ABC kit (Vector Laboratories, UK). These kits were used
as recommended in the manufacturer’s guidelines (Vector
Laboratories, UK). Blocking and secondary incubation was
performed at room temperature whilst primary incubation was
performed at 37uC. Samples were washed twice for five minutes
using 0.1% Tween (v/v) in PBS between each step of the protocol.
3,39diaminobenzidine (DAB) (Vector Laboratories, UK) was used
for substrate staining and Nuclear fast red (Sigma- Aldrich, UK.)
was used as a counter stain.
In addition flexor tendons in the hindpaws of three C57/BL6
mice were experimentally injured by partial surgical laceration.
Lacerated tendons were then treated with either Adaprev or
isotonic PBS (control). At days 24 hours after injury animals were
euthanized and the tendons recovered and processed for wax
embedding as described above.
Immunohistochemical analysis of 7 mm sections was carried out
using specific antibodies to visualise the distribution of the M6P
receptor (CI-M6PR; Abcam, UK), and the TGF-b receptor 1
(TGF-bR1; Abcam, UK), Smad 2 (Abcam, UK) and Smad 3
(Abcam, UK) which using the rabbit ImmPRESS biotinylated kit
(Vector laboratories, UK). Samples were blocked in 2.5% goat
serum (Vector Laboratories, UK) for 1 hour at room temperature
prior to incubation with each antibody at 1:200 (v/v) dilution for 1
hour at 37uC. After PBS wash the ImmPRESS kit was applied for
30 minutes, washed and then DAB reacted. Sections were then
dehydrated through graded alcohols and transferred to xylene
before being mounted on a coverslip. The distribution of these
molecules in the treated tendons was compared with that observed
in unwounded tissues as controls.
Rabbit Operative Model
Thirty Adult New Zealand white rabbits (Harlan, UK) were
used (average weight of 2.5 kg) and randomized to receive either
PBS or Adaprev. Anaesthesia was induced by intramuscular
15 mg/kg Vetalar-V (Pfizer, Surrey, UK) and 0.25 mg/kg
Domitor (Pfizer, UK) and maintained with Isoflurane (Abbott,
UK), Oxygen and nitrous oxide (BOC Healthcare, UK). Reversal
of sedation was performed with Antisedan (Pfizer, UK) 5 mg/ml.
A longitudinal incision was made on the volar surface of the
forepaw between the metacarpophalangeal and proximal inter-
phalangeal joints of the middle digit, under 3 times loupe
magnification (Surgical Acuity, USA). The flexor sheath was
incised. The flexor digitorum profundus tendon was isolated
between the A2 and A4 pulleys and sharply transected. An
immediate tendon repair was performed with 5-0 Prolene
(Ethicon, USA) modified two-strand Kessler repair without an
epitendinous suture. 50 mL of either PBS (control) or Adaprev was
applied to the tendon repair site and surrounding tissue and
allowed to infiltrate for one minute. The skin was reapproximated
with a running 4-0 Prolene suture (Ethicon, USA). Chloramphen-
icol ointment (Abbott, UK) was applied to the wound, and the
Figure 2. Representative histological images of stained flexor tendon adhesions. A. Three week sham treated tendon. B. Three week
600 mM M6P treated tendon C. Eight week sham treated tendon. D. Eight week 600 mM M6P treated tendon. Arrows indicate site of adhesion. Sub
image shows area stained with picosirius red. Note majority of fibres seen type I collagen (red/yellow) with very little type III collagen (green).
Adhesion made up of less densely packed type I collagen fibres. Note sham treated tendon appears more cellular and has a larger area of adhesion
than tendon treated with 600 mM M6P. No adhesion in D. 600 mM M6P treated tendon. Scale bar represents 200 mm.
doi:10.1371/journal.pone.0112672.g002
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Figure 3. In vivo collagen synthesis and cell proliferation by immunohistochemistry. Representative samples were taken from 3 week
injured flexor tendons. A. Sham treated flexor tendon injury stained with antibodies to Hsp47 (collagen synthesis marker). Arrow indicates adhesion. B
Adaprev treated flexor tendon injury. C Quantitative analysis of Hsp47 in tendon and subcutaneous tissues showing no significant difference in
cellular Hsp47 expression between the two groups. D. Sham treated flexor tendon injury stained with antibodies to BrdU (cellular proliferation
marker). Arrow indicates adhesion. Note good staining of basal layer of skin, hair follicles and on the tendon surface. E. Adaprev treated flexor tendon
injury. F. Quantitative analysis of if BrdU in tendon and subcutaneous tissues showing no significant difference in cellular BrdU expression between
the two groups (p.0.05). Error bars represent standard error of mean. Scale bar represents 200 mm.
doi:10.1371/journal.pone.0112672.g003
Figure 4. Effect of Adaprev on Rabbit flexor tendon breaking strength in vivo. No significant difference in breaking strength and tensile
strength between treated and non treated flexor tendons (p.0.05). Error bars represent standard error of mean.
doi:10.1371/journal.pone.0112672.g004
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Figure 5. Cell viability following increasing doses of M6P treatment. A. Live/Dead viability stain used to exhibit cell morphology and cell
viability. Living cells uptake calcein AM (green) Ethidium homodimer taken up by dead cells (red). Untreated cells show spindle shaped morphology
in confluence whereas treated cells with 50 mM retain their spindle morphology at 45 and 60 minutes of exposure. At 200 mM cells begin to lose
Reduction of Tendon Adhesions with M6P
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forepaw was immobilized in an above elbow cast (Lewis-Plast,
UK) with the paw and elbow joints in flexion for two weeks.
Ten Rabbits had liquid sample aspirates collected from the
intra-synovial junction of the treated tendon sheath at 0, 5, 15, 30
and 45 minutes and diluted in water (1:100) followed by a 1:25
dilution in PBS to attain a suitable concentration for high
performance anion exchange with pulsed amperometric detection
(HPAE-PAD) quantification using a Dionex ICS-5000 (Thermo
Scientific, Germany) 20 mL of the diluted sample was injected on a
strong anion exchange column designed for selective carbohydrate
separations. M6P is eluted using a gradient of 47.5 mM sodium
hydroxide (Life Technologies, USA) and 500 mM sodium acetate
at 1 mL/min over 20 min, and detected using a Four-Potential
Waveform.
The remaining 20 rabbits were studied at six weeks postoper-
atively (n = 10 in each group), the animals were killed and the left
forepaw of each rabbit was removed. Tendon’s were harvested
and then tested in an Instron 5542 Tensiometer System (Instron,
USA) controlled by Bluehill2 software (v2.9). Tendons were loaded
longitudinally along the axis of the fibers and distracted at
20 mm/min, using 500N load cell (Instron, USA), as this gave
most reproducible data. Force and extension data were recorded
every 100 ms. Young’s modulus, ultimate load to failure, Max
force and force normalised for cross sectional area were calculated.
Cell viability assay
Freshly harvested C57/Bl mice flexor tendons were digested in
collagenase I (2.5 mg/mL, Sigma-Aldrich, UK) for 3 hours at
37uC, pipetting gently every 30 minutes. Digests were then
centrifuged at 300 g for 15 minutes and resuspended in Dulbecco’s
Modified Eagle Media (DMEM; Life Technologies, UK) with
10% fetal bovine serum (FBS; Life Technologies, UK). These were
grown to confluence for 5 passages and seeded at approximately
20,000 cells per well in a 96 well imaging plate (BD Biosciences,
USA). Wells were rinsed with PBS prior to drug treatment with
50 mM, 200 mM or 600 mM M6P (Adaprev) for 45, 60, or 120
minutes. Control wells were treated with DMEM only or 95%
methanol (Sigma-Aldrich, UK.) for the corresponding times. After
the specified time, wells were washed with PBS and incubated for
30 minutes with 4 mM Ethidium homodimer-1 (EtHD-1) and
2 mM Calcein AM (Molecular Probes LIVE/DEAD viability/
cytotoxicity kit, Life Technologies, USA). All treatments were
performed in triplicates. Images of cell viability were acquired on a
Pathway Bioimager 855 (BD Biosciences, USA) and the following
filter setup: Ex. 360/10, FITC 488/10 and 555/28; Em.
84101(Quad). Images were collected in each well with an offset
from the well centre of 10610 mm and a montage of [363] was
created without gaps. Exposure times for each fluorophore were
calculated automatically and threshold masks were applied to each
image using the automatic feature of the software. The images
were then processed and analysed in ImageJ software. An intensity
threshold of .500 for Calcein AM (live) and .2000 for EtHD-1
(dead) was applied for each channel and the number of live and
dead cells was quantified using the Analyse Particles module (BD
Biosciences, USA). Stress-shielded cells were quantified manually
based on their shape, defined as cells without any cytoplasmic
protrusions, exhibiting a condensed round morphology using
ImageJ [25].
Rat tendon fibroblast culture
Flexor tendons from Male Sprague-Dawley rat hindpaws
(Harlan, UK) were dissected out and placed into L15 air-buffered
culture medium (Sigma-Aldrich, UK) and minced into 5 mm
tissue pieces and seeded into a Petri dish (Corning, USA). After
addition of growth medium (DMEM/10% Foetal Bovine Serum
(FBS) (v/v), tissue was then incubated for 3days to allow fibroblast
outgrowth until cells were 80% confluent.
p38 Immunoblot
Rat hindpaw flexor tendon fibroblasts were seeded at 300,000
cells per well of a 6 well plate (Nunc, Thermo scientific, USA), in
DMEM supplemented with 10% (v/v) FBS, 0.1 mM non-essential
amino acids, 2 mM glutamax (Life Technologies, USA) and 100U
penicillin/100 mg streptomycin (Life Technologies, USA). After
their spindle morphology but continue to have cytoplasmic protrusions with evidence of crenation after 120 minutes of exposure. Cells treated with
600 mM showed fewer cytoplasmic protrusions with a considerable shielded appearance after 60 minutes and 2 hours. B. Quantification of the living
(green) and dead (red) cells revealed the majority of cells were still viable after all treatments with no significant loss of cellular viability (p.0.05). No
significant difference was found between the number of live cells or dead cells found between treatments, dosages or exposure times, except those
observed in the negative control (methanol) (p.0.05). Error bars represent standard error of mean.
doi:10.1371/journal.pone.0112672.g005
Figure 6. Phosphorylation of p38 by Adaprev and G6P. Both Adaprev and G6P significantly increased phosphorylation of p38 when compared
with controls with peak activity between 15 and 60 minutes of exposure.
doi:10.1371/journal.pone.0112672.g006
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one day the cells were serum starved in DMEM supplemented
with 0.1 mM non essential amino acids (Life Technologies, USA),
2 mM glutamax and 100 U penicillin/100 mg streptomycin. The
cells were then treated with Adaprev or 600 mM G6P for 5, 10,
15, 30 and 60 minutes with untreated cells as a control. All
treatments were performed in triplicate. After treatment the cells
were lysed in lysis buffer (Urea [8M], (Life Technologies, USA);
Thiourea [1M], (Sigma-Aldrich, UK), CHAPS [4% w/v] (Sigma-
Aldrich, UK), Dithiothreitol [65 mM], (MP Biomedical, USA)
Protease Inhibitor [0.5% w/v] (Roche, Swtizerland); Phosphatase
Inhibitor 1 [1% w/v], (Sigma-Aldrich, UK) Phosphatase Inhibitor
2 [1% w/v], (Sigma-Aldrich, UK)). Samples were then subjected
to gel electrophoresis, transferred onto nitrocellulose and im-
munoblotted with a phospho-p38 antibody (Cell signalling
technologies, USA).
F-actin cytoskeleton rearrangement
Rat hindpaw flexor tendon fibroblasts were seeded in Nunc
Labtek 8-well chambers at 236103 cells/mL (0.3 mL/well)
(Thermo scientific, USA), in DMEM/10% (v/v) FBS, and
incubated overnight at 37uC/5% CO2. Following incubation,
cells were treated with Adaprev, fixed in 4% formaldehyde for 10
minutes and washed 365 minutes in PBS. Cells were permeabi-
lized in 0.25% (v/v) TRITON-X/PBS (Sigma-Aldrich, UK) for
10 minutes, followed by brief PBS washes, incubated with 1%(w/
v) BSA/PBS (Sigma-Aldrich, UK) for 30 minutes to block non-
specific antibody binding. Finally, cells were briefly washed in PBS
and incubated with Alexafluor phalloidin (1:40 dilution) (Molec-
ular Probes, USA), in 1%(w/v) BSA/PBS, washed in PBS and
incubated for 10 minutes at room temperature with DAPI (1:100
dilution) (Molecular Probes, USA). All treatments were performed
in triplicate. Cells were washed in PBS and were mounted in
Vectashield (Vector laboratories, UK) under a coverslip and
visualised with a Leica DM6000B fluorescent microscope (Leica
Microsystems, Germany) and captured using Leica Application
Suite 2.1.0 (Leica Microsystems, Germany).
Cell Migration Assay (Chemokinesis)
Rat hindpaw flexor tendon fibroblasts in DMEM/10% (v/v)
FBS were seeded into a Corning Costar 24-well plate (Sigma-
Figure 7. Effect of Adaprev and G6P on actin cytoskelaton of rat flexor tendon fibroblasts. Rat flexor tendons were grown in DMEM
containing 10% Fetal Bovine Serum (FBS) and then transferred to media without FBS before either having Adaprev or 600 mM G6P added to the
media. Non treatment controls were maintained in DMEM without serum. Cells were maintained under the above conditions for up to 60 minutes
and photographed at various times to record the cellular effects. At 15 minutes the cells in both groups show ‘‘stress shielding’’ of the actin
cytoskeleton then at 60 minutes similar crenation effects upon both the Adaprev and G6P treated cells were observed.
doi:10.1371/journal.pone.0112672.g007
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Aldrich, UK) at 2.16104 cells/well and incubated overnight. Cells
were treated with Adaprev or 600 mM G6P, washed in sterile PBS
and incubated in DMEM/10%FBS and the movement of 10
fibroblasts per treatment group were assessed using a Leica
DMIRB Inverted timelapse video microscope with phase contrast
(Leica Microsystems, Germany). Control cells were exposed to
DMEM/10%FBS (v/v) (positive control) or DMEM alone
(negative control). Timelapse images were taken every 15 minutes
for 20 hours, at 7.5 times magnification and were imported into
ImageJ software. where cell motility in each treatment was
recorded using the Manual Tracking plugin. Motility data were
imported into the Chemotaxis and Migration Tool plugin (Ibidi,
Germany) to generate plots of migration paths and distances from
a normalised point of origin. Further comparisons between
treatment groups were made determining the percentage of cells
migrating pre-determined distances.
Cell Migration Assay (Chemotaxis)
Rat hindpaw flexor tendon fibroblasts were seeded onto a
Corning 96-well transwell filter (pore size 8 mm) (Corning, USA),
at 56104 cells/filter. DMEM/10% (v/v) FBS was added into the
lower chamber. Cells were incubated overnight to allow adhesion
to the filter. Following incubation, medium was aspirated from
both chambers and filters washed with sterile PBS before
incubating the cells in Adaprev or 600 mM Glucose-6-Phosphate
(G6P) added to both chambers of the transwell, for 0, 15, 30, 45,
60 and 120 minutes. After treatments were performed in triplicate
wells, cells were washed in PBS and cell migration initiated by
adding DMEM/10% (v/v) FBS to the lower chamber of the
transwell, and serum-free DMEM to the upper chamber.
Following overnight incubation, well inserts were treated with
Accutase (Sigma-Aldrich, UK) for 5 minutes to remove migrated
cells from the underside of the filter into a receiver plate. Cell Titre
Glo/10% (v/v) FBS (Promega, UK) was added to the migrated
cells which were shaken for 2 minutes, incubated at room
temperature for 10 minutes, and counted using a 340PC384
SpectraMax plate reader (Molecular Devices, USA).
Cell Proliferation Assay
Rat hindpaw flexor tendon fibroblasts were plated out at 104
cells per well in a 96 well plate (Corning, USA), and incubated
overnight at 37uC. Cells were exposed to Adaprev or G6P
(600 mM), in triplicates, for 15, 30, 45, 60 and 120 minutes.
Following exposure, treatments were removed and all wells
Figure 8. Effect of Adaprev on fibroblast migration (Chemokinesis). A. Control without 10% FBS. B. Control with 10% FBS. C. M6P with 10%
FBS. D. G6P with 10% FBS. Concentric rings indicate 50 mm distance from centre with ten cells measured per treatment group. Note 100% of cells
within 100 mm distance with no FBS. Note 70% of cells had migrated beyond 100 mm in DMEM and 10% FBS controls. Adaprev and G6P treatment
resulted in a reduction of migration with only 20% and 30% of cells migrating beyond 100 mm.
doi:10.1371/journal.pone.0112672.g008
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washed twice with PBS, and wells were treated with growth
medium (DMEM/10% FBS (v/v). Cells without Adaprev or G6P
treatment acted as positive controls. Cell proliferation was
determined using a cell counting kit (CCK-8, Fluka, Sigma-
Aldrich, UK) at 12, 24, 48, 120, 144, 168 and 192 hours post
treatment. The percentage cell proliferation relative to the positive
control (DMEM/10%FBS (v/v) with no treatment) for triplicate
wells was determined.
Ex Vivo Cell Migration and Proliferation
Flexor tendons from six rat hindpaws were dissected out and
placed into L15 air-buffered medium. Tendons were oriented
Figure 9. Effect of Adaprev exposure time on fibroblast proliferation. Proliferation activity was normalised to untreated cells and treated
cells expressed as a percentage of non-template controls. A. Exposure to Adaprev significantly reduced cell proliferation (p,0.05), which gradually
recovered to normal levels in 15 minutes and 30 minutes exposure groups after 120 hours. Longer periods of exposure (45–120 minutes) showed a
significant ‘‘lag phase’’ which gradually recovered to near normal levels at 168 hours B. Treatment with G6P showed similar ‘‘lag phase’’ kinetics. Error
bars represent standard error of mean.
doi:10.1371/journal.pone.0112672.g009
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longitudinally in rat collagen-I matrix (BD Biosciences, USA).
DMEM/10% (v/v) FBS was added and the tendons were
incubated for 48 hours. Medium was then removed and replaced
with Adaprev for one hour. After the 1 hour incubation the
treatment was replaced with DMEM/10%FBS (v/v). Tendons
exposed to DMEM/10%FBS (v/v) alone acted as positive
controls. Tendons were photographed every 24 hours to assess
and compare fibroblast outgrowth from tendons.
Statistical Analyses
All experiments were analysed in a blinded manner by at least
two independent observers and sampled accordingly to generate
mean values expressed with standard error of mean (6). Between
mouse in vivo replicates, treatments were analysed for differences
between groups using paired Student’s t-test based on the null
hypothesis of no difference between active drug treatment and
control. Between rabbit in vivo experiments, treatments were
analysed between groups using independent Student’s t-test based
on the null hypothesis of no difference between active drug
treatment and control. In culture experiments were performed in
at least triplicate and comparisons were made using one-way
ANOVA between treatments using statistical software (IBM SPSS
Statistics v.20). A p value of less than 0.05 was considered to be
significant.
Results
Intrathecal administration of Adaprev reduces in vivo
tendon adhesion formation
Within 24 hours of injecting DiI, the dye was widely distributed
within the tendon sheath (Figure S2) coating the entire length of
the tendon and sheath within the digit. Treatment of tendons with
TGF-b1 increased adhesion formation by 149% and 46% at three
and eight weeks respectively but not found to be statistically
significant.
Treatment with 50 mM and 200 mM M6P had no significant
effect on adhesion formation at three or eight weeks however, the
Adaprev treatment group displayed a reduction in tendon
adhesion formation three weeks post-surgery (mean reduction in
adhesion area of 39% compared to contralateral controls)
although this improvement was not significant. At eight weeks
post-surgery, a significant reduction in tendon adhesion formation
was observed compared to the saline control with Adaprev
treatment (p = 0.02) with a mean percentage reduction in adhesion
area of 47% (Figure 1A). In this group there was also a significant
improvement in tendon organisation as measured by quantitative
polarisation (87.7% normalised treated compared to 32%
normalised controls, p = 0.047) (Figure 1B). Histologically, notable
differences in the amount of adhesion that formed were evident in
600 mM treated tendons when comparing paired samples at both
Figure 10. Ex vivo migration assay. Control cut tendon ends demonstrate a vast number of cells migrating from the tendon after 5
days in DMEM/10%FBS culture medium. Tendon treated in high Adaprev only began showing signs of cell migration at 8 days which gradually
normalised after 11 days.
doi:10.1371/journal.pone.0112672.g010
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three and eight weeks (Figure 2). Staining with picosirius red at 3
and 8 weeks showed less densely packed type I collagen fibres
(red/yellow) at the adhesion site with little evidence of type III
collagen (green). Collagen type I fibres were most evident
throughout the tendon with no discernable difference was
detectable between Adaprev and untreated groups at either 3 or
8 weeks (Figure 2).
Staining for Hsp 47 (marker for collagen synthesis) at 3 weeks as
the point of maximal cellular activity showed increased Hsp 47
expression at the site of skin wound, tendon wound and if present,
adhesion but showed no significant difference between untreated
and Adaprev treated tendons (211639 cells/mm2 vs 202629
cells/mm2 respectively; p.0.05; (Figure 3 ABC). Likewise staining
for cellular proliferation (BrdU) showed no difference no
significant difference between untreated and Adaprev treated
tendons at 3 weeks (2066 cells/mm2 vs 1965 cells/mm2
respectively; p.0.05; (Figure 3 DEF).
TGF-b pathway receptors and downstream target
expression are absent 24 hours after injury
Immunostaining for CI-M6PR, TGFb -R1, SMAD 2 and
SMAD 3 revealed no expression of these receptors in the first 24
hours after injury, which is beyond the expected residency time of
M6P despite positive staining in unwounded controls (Figure S3).
Residency of Adaprev in the flexor sheath is short
Analysis of the biological availability of Adaprev in vivo showed
that over 45 mins there was a significant reduction of bioavailable
M6P in the flexor sheath by 40% (Figure S4).
Treatment with Adaprev did not weaken tendon repairs
Tendons repaired using a standard modified two core Kessler
repair treated with Adaprev did not demonstrate an increased
predisposition to rupture with breaking strengths repair greater
than controls (3.57 N c.f 2.23 N) however this was not statistically
significant (p.0.05). When normalised for tendon cross sectional
area both breaking strength and tensile strength showed no
significant difference between Adaprev and no treated controls
(p.0.05) (Figure 4).
Based on this data 600 mM M6P (Adaprev) was selected as the
most therapeutically active concentration to reduce adhesion
formation without apparent detriment to collagen synthesis or
cellular proliferation at the peak stages of tendon healing and
therefore used to further investigate mechanism of action.
Adaprev was not cytotoxic and induced features of cell
stress
Tendon fibroblasts in culture developed a spindle shaped
morphology in culture but once exposed to increasing doses of
M6P developed increasingly rounder morphologies with all cells
viable (Figure 5 A). The number of completely rounded cells was
quantified (no cytoplasmic protrusions) and shown to present
mostly in the 600 mM M6P treated group at increasing numbers
the longer the cells were exposed (Figure 5B). The number of cells
that was stress-shielded was counted and reported here as a
percentage of the total cells observed (Figure S5). We found that
after 45 mins of 600 mM M6P exposure, just over half (54%) of
cells were stress-shielded, which was significantly more than
compared cells exposed to 200 mM (2.9%, p= 0.038). Indeed,
only 2.3% of cells were found not to be stress-shielded after 2
hours at 600 mM exposure. There was no significant increase in
cell death as measured by ethidium homodimer uptake with
increasing concentration or duration of exposure to M6P (p.
0.05).
Increased concentration of M6P related directly to
increased osmolality
We were surprised by the high number of stress-shielded cells so
we measured the osmolality of the solutions of M6P. We found a
linear relationship with the concentration of M6P (Figure S6) and
the osmolality. 600 mM M6P (Adaprev) was the highest concen-
tration we could reliably reproduce and was considerably
hypertonic at 1500 mOsm, as was 200 mM M6P at 689 mOsm
and to a lesser extent 50 mM M6P at 395 mOsm. We
hypothesised that high osmolar application of M6P may have
biological effects via osmotic shock and therefore we compared
Glucose 6-Phosphate (G6P), a similar sized sugar molecule not
involved in the TGF-b pathway, to see if we could replicate this
effect.
Adaprev has comparable p38 induction as G6P
G6P is a monosaccharide that has similar physical properties
and same molecular weight as M6P (282.12; and same tonicity in
solution), but has a low binding affinity for the CI-M6PR [26] and
therefore has no significant effects in CI-M6PR and little
pharmacological activity (Figure S7). Expression of phosphorylat-
ed p38 was induced by both hypertonic 600 mM G6P and
Adaprev with maximal induction at 15 to 60 minutes (Figure 6) to
a far greater extent than the DMEM/10% FBS (v/v) controls.
Adaprev treatment affects cytoskeletal organisation
similar to G6P
Adaprev treatment of tendon fibroblasts leads to reversible actin
cytoskeletal reorganisation compared to in vitro FBS controls
(Figure 7). Adaprev treatment resulted in a relatively rapid
movement of actin fibres to the cell periphery (within 15 minutes
of exposure), a classical osmotic response triggered by the cell to
maintain its shape (stress-shielding). In the following 30–60
minutes after Adaprev exposure cells began to show signs of
crenation with the actin cytoskeleton forming a network around
the nucleus and losing its spindle shaped morphology. This
‘stressed’ appearance persisted until subsequent dilution of
Adaprev with media changes. Comparable results were observed
with 600 mM G6P indicative of osmosis being a colligative
property.
Adaprev inhibits fibroblast migration
The addition of 10% FBS significantly increased cell movement
in a random walk pattern (Chemokinesis) compared with DMEM
only controls with the mean walk distance for 10 mapped cells
278.2623.32 mm over 20 hours. Following treatment with
Adaprev, cell migration was reduced significantly to a mean of
143.1629.9 mm (p,0.05) (Figure S8). G6P also reduced cell
migration compared to DMEM/10%FBS (v/v) controls but this
was not significant (202.3634.5 mm). Comparing cell migration
away from central 50 mm concentric rings showed that control
tendon fibroblasts cultured in DMEM only solution demonstrated
100% of cells within a 100 mm radius (Figure 8A). Seventy percent
of tendon fibroblasts cultured in DMEM/10%FBS (v/v) migrated
beyond 100 mm (Figure 8B). Tendon fibroblasts treated with
Adaprev however showed only 20% of cells migrated beyond
100 mm (Figure 8C) and those treated with G6P found 30%
migrated beyond 100 mm (Figure 8D).
Transwell plate migration studies (Chemotaxis) found that the
duration of exposure to Adaprev or G6P had a profound effect on
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migration through the transwell plate. Increasing duration of
Adaprev exposure significantly reduced the luminescence from cell
reader by 58% at 15 minutes exposure, 63% at 30 minutes, 91%
at 45 minutes, 92% at 60 minutes and .99% at 120 minutes (p,
0.05). G6P also reduced migratory capacity of fibroblasts but to a
lesser extent by 17% at 15 minutes exposure, 30% at 30 minutes,
44% at 45 minutes, 69% at 60 minutes and .99% at 120 minutes
(p,0.05) (Figure S9).
Adaprev delayed onset of proliferation on cultured
fibroblasts
Fibroblast proliferation was compared to non-treatment con-
trols and found that both Adaprev and G6P had a temporary
inhibitory effect on cell proliferation at increasing levels of
exposure. This demonstrated a significant ‘‘lag phase’’ compared
to normal which for short exposure (15–30 minutes) recovered by
120 hours but with longer exposures (45–120 minutes) recovered
slowly after 168 hours (p,0.05) (Figure 7). The effect of short
exposure of 15 minutes and long exposure of 120 minutes was
found to be significantly different (p,0.05). The effect of duration
of Adaprev exposure on cell proliferation was investigated and
showed that after 15 and 30 minutes exposure to Adaprev in vitro,
little effect on cell proliferation was observed. Increasing exposure
time of the cultured fibroblasts to Adaprev for 45, 60 and 120
minutes resulted in a prolonged ‘‘lag phase’’ of proliferation of four
to five days before cell proliferation began to return to normal
levels (Figure 9).
Adaprev delayed migration and proliferation of
fibroblasts from ex vivo model
The ‘‘lag phase’’ seen in the proliferation studies and reduction
of cell migration effect of Adaprev was mirrored in the ex vivo
whole mount tendon studies. In untreated tendon in DMEM/
10%FBS (v/v) significant outgrowth was seen at 5 days however
after exposure to Adaprev for 1 hour, cells remained within the
tendon, with migration from the tendon ends initiating at
approximately 8 days following treatment with only a normalising
pattern migration occurring at 11 days (Figure 10).
Discussion
The estimated direct cost to healthcare of a poor functioning
finger after flexor tendon injury is approximately $7000, with
indirect costs to society through loss of earnings or workforce
$13200 [27]. There are few effective treatments against tendon
adhesion formation hence potential therapies to combat adhesions
could have a significant healthcare impact. Numerous therapies
have been investigated in order to determine their efficacy in
reducing tendon adhesions and few if any achieve clinical
application [9].
Many studies have shown that M6P reduces tendon adhesions
by antagonism of the TGF-b pathway and proposed the
mechanism of action is via suppression of latent TGF-b activation
[14,20,28]. M6P is a low molecular weight monosaccharide that
competitively binds to CI-M6P receptors, which are required to
activate latent TGF-b1 receptors hence reducing locally available
active TGF-b1 [29]. The proposed mechanisms by which latent
TGF-b is activated include formation of a CI-M6PR complex with
urokinase plasminogen activator receptor (uPAR) which in turn
converts plasminogen to plasmin which in turn activates TGF-b1
[30]. A number of studies have subsequently put this to question
such as Barnes et al. (2012) [18] who have shown that latency
associated peptide of TGF-b1 is not subject to mannose
phosphorylation, hence the addition of M6P has little to no effect
on inhibiting activation of this peptide. To further complicate
these observations it has been shown that CI M6PR may or may
not activate latent TGF beta depending on cell type [31]. However
the amount of latent TGF beta bound to the extracellular matrix
and liberated after injury is likely to be profound [32] and
inhibiting its activity by a short-lived peptide would be difficult to
achieve.
In this study a 600 mM dose of M6P (Adaprev), significantly
caused a 47% reduction in tendon adhesion and a 20%
improvement in collagen alignment at eight weeks post-wounding
for tendon when compared with contralateral controls (p,0.05).
In addition we found little to no effect on collagen synthesis or cell
proliferation at the crucial stages of tendon healing and collagen
architecture showed predominantly normal levels of collagen type
I fibres with the only real difference being the reduction of
adhesions and improvement of organisation of collagen in
Adaprev treated groups. Importantly the treatment of tendons
using Adaprev did not impair the breaking strength of the tendon
and therefore could be used as a safe treatment for the use in the
clinical setting. This is particular important as previous applica-
tions of anti-adhesion therapies such as Adcon T [33] were
withdrawn from clinical use after they were found to increase
rupture rates in clinical trials.
Our study did not show CI-M6PR, TGFb-R1 and downstream
targets such as SMAD 2 and 3 expression in the first 24 hours of
tendon injury in our mouse model suggesting bioavailable M6P
did not mediate its effect through the described TGF-b pathway.
The effect of altering the concentration of M6P was not cytotoxic
to cells even at high doses (600 mM M6P) but did appear to have
profound effect on cell morphology. This prompted us to explore
the osmolality of M6P, which highlighted that concentrations of
50 mM, 200 mM and 600 mM were 395 mOsm, 689 mOsm and
1500 mOsm respectively. We were surprised to find that this
osmolality of sugar did not cause a dramatic loss of cell viability
especially as lesser concentration (500 and 700 mOSm) of sucrose
have shown to induce cell death in odontoblast cell lines [34].
However the bioavailability of M6P had already reduced by 40%
in 45 minutes in our study and as the half-life of M6P is less than
120 minutes in vivo [35], it appears that this is sufficiently short
that the cells recover. In addition tendon fibroblasts may be
particular resistant to the osmotic forces as they regularly tolerate
physical stresses from compression, tension [36] and heat [37]. As
such the possibility of osmotic shock as a potential mechanism for
the biological changes arose.
Cellular responses to hyperosmotic stresses are well described
following exposure to high sodium chloride levels or high urea
levels [38] and exposure to simple sugars such as sorbital and G6P.
Cultured tendon fibroblasts following exposure to hyperosmolar
M6P show rapid actin stress fibre reorganization, results which
were similar to those seen of Swiss 3T3 cells exposed to 0.45M
sucrose [39].
Hyperosmolar G6P, which has a similar molecular weight,
tonicity and composition as M6P, was used as a positive control for
investigating the osmotic shock potential of Adaprev by comparing
phosphorylation of p38 in treated fibroblasts. This is a well
established mitogen activated protein kinase pathway for a
number of causes of cellular stress [40] however it is particularly
sensitive for osmotic stress [41,42] and hence chosen to be
investigated. The increased phosphorylation of p38 in the absence
of inflammation, cell migration and proliferation [43] would
certainly suggest its association with osmotic shock. Indeed the
reconfiguration of the actin cytoskeleton to stress-shielding along
the periphery and crenation are characteristic signs of a cells
response to hypertonicity [44]. These findings supported by the
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reduction of cell migration (both chemokinesis and chemotaxis)
and cause of a ‘‘lag phase’’ in cell proliferation in both in vitro and
ex vivo models are certainly indicators that the normal cellular
wound healing processes are disrupted. Small changes in cell
volume caused by hyperosmotic stress can influence cellular
migration and proliferation [45] however the cells can adapt to
these changes [46]. Studies have shown that osmotic stress can
inhibit proteasome function that is key to a number of biological
processes via p38 MAPK phosphorylation [47], which may
involve cell cycle arrest [48].
The inhibition of both migration and proliferation without
apparent effect on collagen synthesis at critical periods of tendon
healing (3 weeks) may actually be crucial for the effects of reducing
tendon adhesions. The cells lie stationary in their resident tissue
and produce collagen without seeding collagen along a proposed
migratory path. Indeed the effect of 5-Fluorouracil, a chemother-
apeutic drug that has long been reported as having anti-adhesion
properties exerts its effect by reducing cell mitosis and inhibiting
cell migration [49,50]. This potential mechanism of action,
although simplistic, is evident in the results shown and may
actually be of value for developing other treatments for conditions
that involve healing between two gliding tissues.
Other markers to consolidate the role of osmotic stress such as
TonEBP [51] would also be important to investigate however not
within the scope of this study. Future studies will aim to develop
the pharmacological role of osmotic stress as a potential new
direction to reduce tendon adhesions without any detriment to cell
viability and healing. The applications could involve treatments
for peritoneal, tendon and corneal adhesions, effectively any
conditions where scarring occurs between two surfaces restricting
glide.
Taken together the data presented here demonstrate using
in vitro, ex vivo and in vivo experiments that Adaprev appears to
have a mode of action independent of the TGF-b pathway,
possibly via a physical, hyperosmotic effect. At the cellular level
evidence of reversible cell crenation occurs, resulting in a transient
reduction of cellular migration and proliferation, facilitating
fibroblast activity in its resident tissues as opposed to following
growth factor gradients across the wounded environment.
Adaprev may be considered for safe use in the context of flexor
tendon surgery, and the use of hypertonic solutions in reducing cell
migration and proliferation should warrant further investigation in
other tissue types where glide is important for physiological
function.
Supporting Information
Figure S1 Quantification method for adhesion forma-
tion. A. Quantification of length of adhesion. Arrow denotes
adhesion site. A stereological measurement over five equally
spaced sections is used to provide an estimation of the adhesion
area. B. Quantification of the area of tendon. Arrow denotes
adhesion site. A stereological measurement over five equally
spaced sections is used to provide an estimation of tendon area. C
and D show quantification method for percentage of tendon
polarisation. C. Outline of tendon is transferred from standard
histology image (B). Note arrow shows adhesion as non polarising
area. D. All areas that are polarised are measured to give overall
ratio of polarised tendon area to non- polarised tendon area. This
is measured over three equally spaced sections and a mean value is
calculated. Scale bar represents 200 mm.
(TIF)
Figure S2 Distribution analysis of DiI injected into
wound and sheath space. Fluorescence microscopy of A.
sheath space injected DiI at time point zero. B. sheath space
injected DiI at 24 hours. DiI in red. Three dimensional
reconstruction of digit showing C. DiI distribution at zero hours
and D. DiI distribution at 24 hours. DiI is represented in red,
Sheath space is represented in light blue, Bone is represented in
orange and subcutaneous tissue is represented in green. Scale bar
represents 200 mm.
(TIF)
Figure S3 Immunohistochemistry of mouse hind paw
flexor tendon following surgical laceration. Cation inde-
pendent Mannose 6 phosphate receptor (CI-M6PR) expression is
shown in A and Transforming growth factor b Receptor 1 (TGFb-
R1) expression is shown in B. Downstream signaling molecules
Smad 2 and Smad 3 are shown in C. and D. respectively. Images
show longitudinal section of lacerated tendon following. i) shows
staining for unwounded controls, all showing evidence of baseline
staining in the extracellular matrix and serving as positive controls.
After injury PBS treated sham controls (ii) and Adaprev treated
tendons (iii) show no evidence of CI-M6PR or TGFb-R1
expression and no increased expression of downstream Smad 2
or 3. Arrows indicate the point at which the tendon was lacerated
and T= tendon. Magnification x10.
(TIF)
Figure S4 Residency of Adaprev over time in the flexor
tendon sheath. A gradual reduction in bioavailable Adaprev
was noted in the flexor sheath with time with 14%, 29%, 28% and
40% decreases in recoverable concentration found at 5, 15, 30 and
45 minutes respectively. Error bars represent standard error of
mean. * denotes significant reduction where p,0.05.
(TIF)
Figure S5 Quantification of ‘‘stress shielded’’ (SS)
morphology in cell viability assay. With 50 mM and
200 mM concentration cells did not show many stress shielded
phenotypes until exposure was over 120 minutes (% SS 11.861
and 14.1618 respectively). However 600 mM concentrations
number of SS cells increased dramatically to 53.962.2, 85.268.9
and 97.7618% with respect to 45 minute, 1 hour or 2 hours worth
of exposure. Error bars represent standard error of mean. *
denotes significant increase where p,0.05.
(TIF)
Figure S6 Concentration relationship to Osmolality of
Mannose 6-Phosphate. A linear response to increasing
concentration to osmolality was demonstrated.
(TIF)
Figure S7 Comparison of molecular weight and struc-
ture of M6P and G6P. The molecular weight of the two sugars
is identical however G6P has no binding affinity of CI-M6PR.
(TIF)
Figure S8 Mean migration distance of tendon fibro-
blasts following treatment with Adaprev and G6P. Cells
did not migrate far without the addition of 10% FBS (45.7 mm
versus 278.2 mm). The addition of Adaprev significantly reduced
the migration distance of cells (143629 mm) (p,0.05) whereas
G6P also reduced cell migration, this was not found to be
significant (202.3634.5 mm) (p.0.05). Error bars represent
standard error of mean.
(TIF)
Figure S9 Migration of fibroblasts as measured by Cell
Titer Glo Luminescence with increasing exposure times
to Adaprev or G6P. Both treatments led to a significant
reduction of mean luminescence indicating reduced cell migration
Reduction of Tendon Adhesions with M6P
PLOS ONE | www.plosone.org 14 November 2014 | Volume 9 | Issue 11 | e112672
with increasing duration of treatment exposure. Error bars
represent standard error of mean. Adaprev was significantly more
effective at reducing cell migration after 45 and 60 minutes of
exposure. * denotes significant difference where p,0.05. Error
bars represent standard error of mean.
(TIF)
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